Nuvalent, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 25.19 million compared to USD 17.55 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.36 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.43 USD | +0.59% | -0.37% | -9.73% |
05-17 | Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing | MT |
05-16 | Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 4.26B | |
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- NUVL Stock
- News Nuvalent, Inc.
- Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023